Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Travel Awards - Institute Community Support

Direct Payment

$879.00

Effect of bone marrow-derived syngeneic late outgrowth endothelial progenitor cells in pulmonary hypertension

FY 2013-14

Summary
Pulmonary hypertension (PH) is an increase of blood pressure in the lung blood vessels that leads to shortness of breath, dizziness, fainting and other symptoms. PH is a serious disease, and average survival is 5-yars after diagnosis. Scientific community believes that one of the major causes of the PH is the death of endothelial cells (the cells that form the innermost layer of the blood vessels) of lung blood vessels. Our lab studies the stem cells called endothelial progenitor cells (EPCs). These cells are believed to be the precursor cells for the endothelial cells. These cells are can be obtained from various tissues such as lung small blood vessels, blood, bone marrow and spleen. For our experiments we have derived these cells from rat bone marrow. We believe that these bone marrow-derived EPCs, if injected into the lung blood vessels, can help repair the damaged blood vessels of the lungs and prevent progression of PH. To study the effect of these cells in treatment of PH we used a rat model of PH. Rats were injected with a plant toxin (monocrotaline; MCT) to induce PH. MCT injection caused hallmark signs of PH in the rats that are increased pressure in right side of the heart (right ventricular systolic pressure; RVSP) and right side heart enlargement (RV hypertrophy). Treatment with EPCs decreased the RVSP and RV hypertrophy and improved the survival as compared to the control animals. Together, we report beneficial effects of EPCs in preventing PH.
Program
Travel Awards - Institute Community Support
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
304341
Name
Chaudhary Ketul R
Region
Ontario
Country
Canada
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Institute of Circulatory and Respiratory Health
Projecttitle
Effect of bone marrow-derived syngeneic late outgrowth endothelial progenitor cells in pulmonary hypertension
Programtype2
Undefined
Orgnameinp2
Direct Payment
Cihramount2
$879
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Endothelial Colony Forming Cells; Endothelial Progenitor Cell; Monocrotaline; Pulmonary Hypertension; Stem Cells; Vascular Repair
Abstract
Pulmonary hypertension (PH) is an increase of blood pressure in the lung blood vessels that leads to shortness of breath, dizziness, fainting and other symptoms. PH is a serious disease, and average survival is 5-yars after diagnosis. Scientific community believes that one of the major causes of the PH is the death of endothelial cells (the cells that form the innermost layer of the blood vessels) of lung blood vessels. Our lab studies the stem cells called endothelial progenitor cells (EPCs). These cells are believed to be the precursor cells for the endothelial cells. These cells are can be obtained from various tissues such as lung small blood vessels, blood, bone marrow and spleen. For our experiments we have derived these cells from rat bone marrow. We believe that these bone marrow-derived EPCs, if injected into the lung blood vessels, can help repair the damaged blood vessels of the lungs and prevent progression of PH. To study the effect of these cells in treatment of PH we used a rat model of PH. Rats were injected with a plant toxin (monocrotaline; MCT) to induce PH. MCT injection caused hallmark signs of PH in the rats that are increased pressure in right side of the heart (right ventricular systolic pressure; RVSP) and right side heart enlargement (RV hypertrophy). Treatment with EPCs decreased the RVSP and RV hypertrophy and improved the survival as compared to the control animals. Together, we report beneficial effects of EPCs in preventing PH.
Competitiondate
201401
Approvedterm2
0 yr 3 mths
Pinamesdelim
Chaudhary, Ketul R
Approvedterm
0 an 3 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $879~ $0~